ICIs have also been demonstrated to be efficacious in metastatic colorectal cancer (mCRC) with mismatch repair deficiency (dMMR) or high microsatellite instability (MSI-H), which were characterized by high mutational burden, tumor-infiltrating lymphocytes enrichment, and up-regulated PD-L1 expression within the tumor microenvironment (3, 4). This evidence concerns the gene CD274 and neoplasm.